Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Doxycycline · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Doxycycline Tablets, 150mg |
| 2 | ACTIVE_COMPARATOR | Adoxa Tablets 150 mg |
| Name | Type | Description |
|---|---|---|
| Doxycycline Tablets, 150mg | DRUG | 150mg, single dose fasting |
| Adoxa Tablets 150 mg | DRUG | 150mg, single dose fasting |
| Doxycycline Monohydrate Tablets 100 mg | DRUG | 100mg, single dose fed |
| Adoxa Tablets 100 mg | DRUG | 100mg, single dose fed |
| Doxycycline Monohydrate Tablets (100 mg | DRUG | 100mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the ev...
Doxycycline is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is being studied in Phase 1 clinical development, with three completed trials conducted in healthy adult volunteers in the United States. The specific therapeutic indication for this program is undisclosed.
Doxycycline targets MMP8, MMP1, MMP13, and MMP7, a set of matrix metalloproteinases. It acts as an inhibitor of these targets. This target profile distinguishes the program from other doxycycline-based products, which typically act through antibacterial mechanisms rather than MMP inhibition.
Doxycycline is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor of the clinical program evaluating this small molecule. The company has completed three Phase 1 trials of the drug in healthy volunteers.
Doxycycline is in Phase 1 clinical development. Three Phase 1 trials have been completed, and none are currently active. The program has enrolled a total of 107 participants across these completed studies, all conducted in the United States.
Three completed Phase 1 trials have evaluated Doxycycline: NCT00649571, a fasting study of 100 mg tablets in 35 healthy volunteers; NCT00648180, a food study of 100 mg tablets in 36 healthy volunteers; and NCT00647959, a fasting study of 150 mg tablets in 36 healthy volunteers. All were active-controlled and conducted in the United States.